GlobeNewswire News Roomยท2025-07-26 07:00Core Insights - Assembly Biosciences, Inc. presented Phase 1a clinical and preclinical data for its herpes simplex virus helicase-primase inhibitor candidates ABI-5366 and ABI-1179 at major conferences in July 2025, indicating progress in their development [1][2][4] Clinical Data - Phase 1a clinical data for ABI-5366 and ABI-1179 showed promising safety and pharmacokinetic profiles in healthy participants, supporting their advancement to Phase 1b evaluation [2][4] - Interim proof-of-concept Phase 1b data for both candidates in participants with recurrent genital herpes is expected in fall 2025 [1] Treatment Innovation - ABI-5366 and ABI-1179 have the potential for less frequent dosing, with ABI-5366 offering once monthly and ABI-1179 once weekly oral dosing, which could significantly reduce the treatment burden compared to current daily therapies [2][10] - The current standard of care for recurrent genital herpes has not seen new drug approvals in over 25 years, highlighting the need for innovative treatments [10] Preclinical Insights - Additional presentations at the STI & HIV 2025 World Congress included preclinical studies and methodologies for estimating genital herpes prevalence and treatment patterns in the U.S. [3][8] Company Background - Assembly Biosciences is focused on developing innovative small-molecule therapeutics for serious viral diseases, including herpesvirus infections [12]